南非临床分离株的 manogepix 药敏试验。
manogepix susceptibility testing of South African , and clinical isolates.
机构信息
National Institute for Communicable Diseases (NICD), a Division of the National Health Laboratory Service, Johannesburg, South Africa.
School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Witwatersrand, South Africa.
出版信息
Antimicrob Agents Chemother. 2023 Dec 14;67(12):e0110423. doi: 10.1128/aac.01104-23. Epub 2023 Nov 16.
Abstract
We performed antifungal susceptibility testing of manogepix against the yeast phase of 78 , 2 and 5 isolates using a reference broth microdilution method following Clinical and Laboratory Standards Institute recommendations. All three pathogens had low minimum inhibitory concentrations ranging from <0.0005 to 0.008 mg/L. Manogepix should be investigated in animal models and potentially in future human clinical trials for endemic mycoses.
摘要
我们使用参考肉汤微量稀释法，按照临床和实验室标准协会的建议，对 78、2 和 5 株念珠菌的酵母相进行了曼戈匹克斯的抗真菌药敏试验。所有三种病原体的最低抑菌浓度都很低，范围在<0.0005 至 0.008mg/L 之间。曼戈匹克斯应该在动物模型中进行研究，并有可能在未来的人类临床试验中用于地方性真菌感染。
相似文献
1
manogepix susceptibility testing of South African , and clinical isolates.
Antimicrob Agents Chemother. 2023 Dec 14;67(12):e0110423. doi: 10.1128/aac.01104-23. Epub 2023 Nov 16.
2
Antifungal Susceptibility of Yeast and Mold Phases of Isolates of Dimorphic Fungal Pathogen Emergomyces africanus (Formerly Emmonsia sp.) from HIV-Infected South African Patients.
J Clin Microbiol. 2017 Jun;55(6):1812-1820. doi: 10.1128/JCM.02524-16. Epub 2017 Mar 29.
3
Human Blastomycosis in South Africa Caused by and sp. nov., 1967 to 2014.
J Clin Microbiol. 2020 Feb 24;58(3). doi: 10.1128/JCM.01661-19.
4
Cross-reactivity of a Histoplasma capsulatum antigen enzyme immunoassay in urine specimens from persons with emergomycosis in South Africa.
Med Mycol. 2021 Jul 6;59(7):672-682. doi: 10.1093/mmy/myaa100.
5
Antifungal Activity of Manogepix and Other Antifungal Agents against South African Isolates from Bloodstream Infections.
Microbiol Spectr. 2022 Feb 23;10(1):e0171721. doi: 10.1128/spectrum.01717-21.
6
Emergomycosis, an Emerging Systemic Mycosis in Immunocompromised Patients: Current Trends and Future Prospects.
Front Med (Lausanne). 2021 Apr 23;8:670731. doi: 10.3389/fmed.2021.670731. eCollection 2021.
7
Antifungal Susceptibility of Emerging Dimorphic Pathogens in the Family Ajellomycetaceae.
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01886-17. Print 2018 Jan.
8
Review: Emergomycosis.
J Mycol Med. 2023 Mar;33(1):101313. doi: 10.1016/j.mycmed.2022.101313. Epub 2022 Jul 23.
9
Emergomycosis, an Emerging Thermally Dimorphic Fungal Infection: A Systematic Review.
J Fungi (Basel). 2023 Oct 23;9(10):1039. doi: 10.3390/jof9101039.
10
Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017.
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00840-19. Print 2019 Aug.
本文引用的文献
1
Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris Results from a Phase 2 Trial.
Antimicrob Agents Chemother. 2023 May 17;67(5):e0141922. doi: 10.1128/aac.01419-22. Epub 2023 Apr 6.
2
Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers.
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0162322. doi: 10.1128/aac.01623-22. Epub 2023 Mar 29.
3
Efficacy of APX2039 in a Rabbit Model of Cryptococcal Meningitis.
mBio. 2022 Dec 20;13(6):e0234722. doi: 10.1128/mbio.02347-22. Epub 2022 Oct 12.
4
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.
Drugs. 2021 Oct;81(15):1703-1729. doi: 10.1007/s40265-021-01611-0. Epub 2021 Oct 9.
5
Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology.
Lancet Infect Dis. 2021 Dec;21(12):e364-e374. doi: 10.1016/S1473-3099(21)00191-2. Epub 2021 Aug 6.
6
Therapeutic Potential of Fosmanogepix (APX001) for Intra-abdominal Candidiasis: from Lesion Penetration to Efficacy in a Mouse Model.
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02476-20.
7
Efficacy and Pharmacokinetics of Fosmanogepix (APX001) in the Treatment of Endophthalmitis and Hematogenous Meningoencephalitis in Nonneutropenic Rabbits.
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.01795-20.
8
Endemic Mycoses: What's New About Old Diseases?
Curr Clin Microbiol Rep. 2016;3(2):71-80. doi: 10.1007/s40588-016-0034-6. Epub 2016 Mar 18.
9
Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus.
Antimicrob Agents Chemother. 2020 May 21;64(6). doi: 10.1128/AAC.00178-20.
10
Human Blastomycosis in South Africa Caused by and sp. nov., 1967 to 2014.
J Clin Microbiol. 2020 Feb 24;58(3). doi: 10.1128/JCM.01661-19.
Zotero 插件